PTGS2 and breast cancer: In the present report, we studied the anti-neoplastic and mitochondrial effects of DEA and combined the cytotoxic effect of DEA and the selective COX-2 inhibitor celecoxib on a TN line in comparison with a hormone receptor positive (HR+) BC line to identify potential differences in DEA’s molecular mechanisms in these two cancer types.